Format

Send to

Choose Destination
Nat Rev Cancer. 2003 Feb;3(2):102-9.

Inhibiting the p53-MDM2 interaction: an important target for cancer therapy.

Author information

1
Novartis, K125 443, CH-4002 Basel, Switzerland. patrick_chene@yahoo.com

Abstract

p53 is an attractive therapeutic target in oncology because its tumour-suppressor activity can be stimulated to eradicate tumour cells. Inhibiting the p53-MDM2 interaction is a promising approach for activating p53, because this association is well characterized at the structural and biological levels. MDM2 inhibits p53 transcriptional activity, favours its nuclear export and stimulates its degradation, so inhibiting the p53-MDM2 interaction with synthetic molecules should lead to p53-mediated cell-cycle arrest or apoptosis in p53-positive stressed cells.

PMID:
12563309
DOI:
10.1038/nrc991
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center